Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention
Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This article aims to review currently identified mechanisms of resistance and the emergence of bedaquiline re...
Saved in:
| Published in: | Clinical infectious diseases Vol. 66; no. 10; p. 1625 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
02.05.2018
|
| ISSN: | 1537-6591, 1537-6591 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This article aims to review currently identified mechanisms of resistance and the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. In vitro and clinical studies as well as reports from compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. Currently known mechanisms of resistance include mutations within the atpE, Rv0678, and pepQ genes. The development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed. Understanding any target and non-target-based mechanisms is essential to minimize resistance development and treatment failure and help to develop appropriate DST for bedaquiline and genetic-based resistance screening. |
|---|---|
| AbstractList | Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This article aims to review currently identified mechanisms of resistance and the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. In vitro and clinical studies as well as reports from compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. Currently known mechanisms of resistance include mutations within the atpE, Rv0678, and pepQ genes. The development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed. Understanding any target and non-target-based mechanisms is essential to minimize resistance development and treatment failure and help to develop appropriate DST for bedaquiline and genetic-based resistance screening. Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This article aims to review currently identified mechanisms of resistance and the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. In vitro and clinical studies as well as reports from compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. Currently known mechanisms of resistance include mutations within the atpE, Rv0678, and pepQ genes. The development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed. Understanding any target and non-target-based mechanisms is essential to minimize resistance development and treatment failure and help to develop appropriate DST for bedaquiline and genetic-based resistance screening.Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This article aims to review currently identified mechanisms of resistance and the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. In vitro and clinical studies as well as reports from compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. Currently known mechanisms of resistance include mutations within the atpE, Rv0678, and pepQ genes. The development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed. Understanding any target and non-target-based mechanisms is essential to minimize resistance development and treatment failure and help to develop appropriate DST for bedaquiline and genetic-based resistance screening. |
| Author | Bañuls, Anne-Laure Vu, Dinh Hoa Alffenaar, Jan-Willem C Nguyen, Thi Van Anh Anthony, Richard M |
| Author_xml | – sequence: 1 givenname: Thi Van Anh surname: Nguyen fullname: Nguyen, Thi Van Anh organization: LMI Drug Resistance in South East Asia, Hanoi, Vietnam – sequence: 2 givenname: Richard M surname: Anthony fullname: Anthony, Richard M organization: Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, The Netherlands – sequence: 3 givenname: Anne-Laure surname: Bañuls fullname: Bañuls, Anne-Laure organization: Laboratory of Tuberculosis, Department of Bacteriology, National Institute of Hygiene and Epidemiology of Vietnam – sequence: 4 givenname: Thi Van Anh surname: Nguyen fullname: Nguyen, Thi Van Anh organization: Laboratory of Tuberculosis, Department of Bacteriology, National Institute of Hygiene and Epidemiology of Vietnam – sequence: 5 givenname: Dinh Hoa surname: Vu fullname: Vu, Dinh Hoa organization: Department of Clinical Pharmacy and National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Vietnam – sequence: 6 givenname: Jan-Willem C surname: Alffenaar fullname: Alffenaar, Jan-Willem C organization: University of Groningen, University Medical Center Groningen, Clinical Pharmacy and Pharmacology, The Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29126225$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj09Lw0AUxBep2D968QNIjh4a3bebTbOerKVqoaKInsPr7ouuJJs2m4h-ewNW8DDMDPwYmDEb-NoTY6fAL4BreWmc7fWltThgI1ByFqdKw-BfHrJxCB-cA2RcHbGh0CBSIdSIXd-QxV3nSucpeqbgQove0FW0akO0rKh5o75Oowcy7-hdqKYRehs9NfRJvnW1P2aHBZaBTvY-Ya-3y5fFfbx-vFst5uvYSAFtbBPkUm4wywqDEiQqSpU0meJqo0koQUplpiAzS4RNtNW8KMDOEAxyQGHFhJ3_7m6betdRaPPKBUNliZ7qLuSgUylSnSVJj57t0W5Tkc23jauw-c7_Xosf6ZpaQg |
| CitedBy_id | crossref_primary_10_3390_microorganisms9061158 crossref_primary_10_3390_microorganisms11071809 crossref_primary_10_1016_j_bmcl_2020_127172 crossref_primary_10_1186_s12879_025_11067_2 crossref_primary_10_1016_j_jpba_2025_117093 crossref_primary_10_1016_j_ijpharm_2023_123018 crossref_primary_10_1128_aac_00124_24 crossref_primary_10_1016_j_jgar_2023_05_001 crossref_primary_10_1016_j_mimet_2018_08_011 crossref_primary_10_1016_j_ejmech_2025_117889 crossref_primary_10_1007_s13738_022_02737_y crossref_primary_10_1016_j_cell_2023_04_009 crossref_primary_10_1097_JNC_0000000000000242 crossref_primary_10_3389_fmed_2023_1304857 crossref_primary_10_3389_fcimb_2022_807095 crossref_primary_10_1016_j_jgar_2021_02_017 crossref_primary_10_4103_ijmy_ijmy_40_23 crossref_primary_10_1016_j_jbc_2025_108288 crossref_primary_10_1186_s13756_021_00995_8 crossref_primary_10_1016_j_molstruc_2023_135359 crossref_primary_10_1128_AAC_00479_20 crossref_primary_10_1099_mgen_0_000620 crossref_primary_10_1039_D5SC02565F crossref_primary_10_2147_IDR_S457308 crossref_primary_10_3390_antibiotics11070831 crossref_primary_10_1038_s41598_021_87117_x crossref_primary_10_1186_s12879_022_07865_7 crossref_primary_10_1016_j_bioactmat_2024_05_013 crossref_primary_10_3390_antibiotics10060693 crossref_primary_10_1002_slct_202100181 crossref_primary_10_1016_j_omtn_2022_07_004 crossref_primary_10_1128_AAC_00292_19 crossref_primary_10_1371_journal_pone_0217169 crossref_primary_10_1128_AAC_02530_18 crossref_primary_10_1016_j_micinf_2023_105279 crossref_primary_10_21292_2075_1230_2020_98_1_54_61 crossref_primary_10_1016_j_micpath_2022_105507 crossref_primary_10_1002_jcla_25091 crossref_primary_10_1093_cid_ciz334 crossref_primary_10_1183_13993003_00361_2021 crossref_primary_10_1128_cmr_00180_19 crossref_primary_10_1016_j_jctube_2025_100536 crossref_primary_10_1007_s00284_022_02881_x crossref_primary_10_1039_c8mt00316e crossref_primary_10_1093_clinchem_hvaa092 crossref_primary_10_1111_bcp_15925 crossref_primary_10_1080_1062936X_2022_2066175 crossref_primary_10_1016_j_cell_2023_01_043 crossref_primary_10_1093_jacamr_dlac029 crossref_primary_10_1093_cid_ciad596 crossref_primary_10_1186_s12866_022_02582_2 crossref_primary_10_1080_14756366_2021_1919889 crossref_primary_10_1080_17425255_2021_1836158 crossref_primary_10_1099_jmm_0_001439 crossref_primary_10_1016_S1473_3099_25_00218_X crossref_primary_10_1016_j_tube_2024_102572 crossref_primary_10_1016_j_meegid_2025_105797 crossref_primary_10_1093_cid_ciz1107 crossref_primary_10_1186_s12879_020_05075_7 crossref_primary_10_1128_spectrum_02549_22 crossref_primary_10_1093_jacamr_dlae037 crossref_primary_10_1186_s13073_020_00793_8 crossref_primary_10_1371_journal_pone_0223308 crossref_primary_10_3390_pharmaceutics13050592 crossref_primary_10_1128_AAC_01849_20 crossref_primary_10_1073_pnas_2111899118 crossref_primary_10_1136_bmjgh_2024_018220 crossref_primary_10_3389_fmicb_2022_974428 crossref_primary_10_1002_psp4_12768 crossref_primary_10_3390_ijms20122868 crossref_primary_10_1016_j_ijantimicag_2023_106953 crossref_primary_10_1016_j_jgar_2022_01_026 crossref_primary_10_1016_j_sciaf_2025_e02627 crossref_primary_10_1128_AAC_01489_18 crossref_primary_10_3390_pathogens12050652 crossref_primary_10_1016_j_ijbiomac_2019_05_108 crossref_primary_10_5588_ijtldopen_25_0240 crossref_primary_10_1016_j_coph_2021_05_007 crossref_primary_10_1093_jac_dkab057 crossref_primary_10_1039_D4MD00829D crossref_primary_10_1007_s00044_024_03295_z crossref_primary_10_1016_j_ijid_2020_07_044 crossref_primary_10_1371_journal_pone_0220684 crossref_primary_10_1128_AAC_00175_18 crossref_primary_10_1080_17460441_2024_2319042 crossref_primary_10_1016_S1473_3099_22_00875_1 crossref_primary_10_1016_j_lfs_2021_119301 crossref_primary_10_1183_13993003_00621_2021 crossref_primary_10_1128_spectrum_03749_23 crossref_primary_10_1080_24745332_2022_2039499 crossref_primary_10_1093_cid_ciaa1002 crossref_primary_10_1007_s40262_021_00997_0 crossref_primary_10_1128_AAC_00665_19 crossref_primary_10_1186_s12889_021_11427_y crossref_primary_10_1016_j_bmcl_2019_04_034 crossref_primary_10_3389_fmicb_2021_754249 crossref_primary_10_1093_jacamr_dlae086 crossref_primary_10_3389_fmicb_2019_00309 crossref_primary_10_1093_cid_ciaf068 crossref_primary_10_1080_24745332_2023_2226006 crossref_primary_10_1016_j_vaccine_2019_10_072 crossref_primary_10_1002_cmdc_202300015 crossref_primary_10_1093_bioinformatics_btaf232 crossref_primary_10_3389_fmicb_2019_00794 crossref_primary_10_1371_journal_pone_0249841 crossref_primary_10_1097_INF_0000000000002857 crossref_primary_10_1097_QAI_0000000000002940 crossref_primary_10_2147_IJGM_S538660 crossref_primary_10_1080_1062936X_2023_2225872 crossref_primary_10_3389_fcimb_2021_707244 crossref_primary_10_1016_j_jgar_2019_06_013 crossref_primary_10_1016_j_micpath_2024_107116 crossref_primary_10_1016_j_bcab_2024_103381 crossref_primary_10_1002_ddr_21498 crossref_primary_10_1007_s44337_025_00493_5 crossref_primary_10_1080_07391102_2023_2279699 crossref_primary_10_2147_IDR_S390187 crossref_primary_10_1164_rccm_201909_1874ST crossref_primary_10_1038_s44386_025_00008_3 crossref_primary_10_1155_2020_8823764 crossref_primary_10_3390_scipharm89020019 crossref_primary_10_1016_j_ijid_2020_10_081 crossref_primary_10_1128_aac_01749_21 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1093/cid/cix992 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| ExternalDocumentID | 29126225 |
| Genre | Journal Article |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 1KJ 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQKUS ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KAQDR KBUDW KOP KSI KSN L7B M49 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8 ABPQP ADNBA AEMQT AFYAG AJBYB AJNCP ALXQX JXSIZ |
| ID | FETCH-LOGICAL-c321t-d4a033ba88fca313a5e653c8505b9e252e558cfec742d49d90ff1d7a1ca01a2d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 142 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000432184200026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6591 |
| IngestDate | Sun Sep 28 01:34:01 EDT 2025 Wed Feb 19 02:43:03 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c321t-d4a033ba88fca313a5e653c8505b9e252e558cfec742d49d90ff1d7a1ca01a2d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 29126225 |
| PQID | 1963269844 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1963269844 pubmed_primary_29126225 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-02 |
| PublicationDateYYYYMMDD | 2018-05-02 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAlternate | Clin Infect Dis |
| PublicationYear | 2018 |
| SSID | ssj0011805 |
| Score | 2.608286 |
| Snippet | Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1625 |
| Title | Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29126225 https://www.proquest.com/docview/1963269844 |
| Volume | 66 |
| WOSCitedRecordID | wos000432184200026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvDY0Owmm8168UWLHlqKKPQWtrsTyMGkNa34851NE3oSBC-5hCxhZnb2m_3mQciNlFYqfOVpxVxJDgYoKlKxFwSW61AZa6Wthk3I4TAej9WovnAr67TKxidWjtoWxt2Rd52lcFwlDO-mM89NjXLsaj1CY520AoQyLqVLjlcsAourFEbc1NKLhGJNe1IVdA2q2mTfqqJAf4GW1RHT3_3vz-2RnRpc0oelNeyTNcgPyNagps8Pyf0jWD1bZA5a0lcoHXZEpd_Sl3lJe3UhJnToAFw9cFZ-dKjOLW3aPBX5EXnv996enr16hIJnAs7mng21HwQTHcep0SgiLSASgYkR90wUcMFBiNikYDBCtqGyyk9TZqVmRvtMc8uPyUZe5HBKKAutDwYEnqoQWqPUhDMNE6mEDxgGmTa5bmSToIk63kHnUCzKZCWdNjlZCjiZLntpJBxNJEKfcvaHr8_JNsKVuEo35BekleIGhUuyab7mWfl5Veken8PR4AfCPbog |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bedaquiline+Resistance%3A+Its+Emergence%2C+Mechanism%2C+and+Prevention&rft.jtitle=Clinical+infectious+diseases&rft.au=Nguyen%2C+Thi+Van+Anh&rft.au=Anthony%2C+Richard+M&rft.au=Ba%C3%B1uls%2C+Anne-Laure&rft.au=Vu%2C+Dinh+Hoa&rft.date=2018-05-02&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=66&rft.issue=10&rft.spage=1625&rft_id=info:doi/10.1093%2Fcid%2Fcix992&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon |